Article
作者: De Stefano, Valerio ; Rossi, Elena ; Tafuri, Agostino ; Lugli, Elisabetta ; Di Ianni, Mauro ; Santoro, Cristina ; Battistini, Roberta ; Zaja, Francesco ; Mazzucconi, Maria Gabriella ; Patriarca, Andrea ; Martino, Bruno ; Di Renzo, Nicola ; Vincelli, Iolanda Donatella ; Gugliotta, Luigi ; Avvisati, Giuseppe ; Sibilla, Silvia ; Vianelli, Nicola ; Crugnola, Monica ; Bocchia, Monica ; Fazi, Paola ; Sargentini, Valeria ; Baldacci, Erminia ; Fortuna, Stefania ; Carli, Giuseppe ; Rodeghiero, Francesco ; Polverelli, Nicola ; Musto, Pellegrino ; Rivolti, Elena ; Paoloni, Francesca ; Ruggeri, Marco ; Gentile, Massimo ; D'Adda, Mariella ; Ranalli, Paola ; Ferretti, Antonietta ; Giuffrida, Anna Chiara ; Palandri, Francesca ; Rago, Angela ; Siragusa, Sergio ; Krampera, Mauro ; Carella, Angelo Michele
AbstractA debate exists regarding which type of corticosteroids (standard-dose prednisone [PDN] or high-dose dexamethasone [HD-DXM]) is the best first-line treatment for adult patients with newly diagnosed untreated primary immune thrombocytopenia (pITP). An ad hoc study compared PDN with HD-DXM in newly diagnosed untreated patients with pITP (aged ≥18 but ≤80 years, platelet count of ≤20 or >20 but <50 × 109/L, and bleeding score of ≥8). Patients were randomised to receive PDN 1 mg/kg per day from days 0 to 28 (Arm A) or HD-DXM 40 mg per day for 4 days, every 14 days, for 3 consecutive courses (Arm B). Fifty-nine of 113 patients (52.2%) were randomized to Arm A and 54 of 113 (47.8%) to Arm B. In evaluable patients, total initial responses (complete response [CR], partial response [PR], minimal response [MR]) were 44 of 56 (78.57%) in Arm A and 46 of 49 (93.88%) in Arm B at days 42 and 46, respectively (P = 0.0284). Total final responses (at day 180 from initial response) were 26 of 43 (60.47%) in Arm A and 23 of 39 (58.97%) in Arm B (P = 0.8907). Total persistent responses (at 12 months from initial response) were 25 of 31 (80.65%) in Arm A and 20 of 36 (55.56%) in Arm B (P = 0.0292). Seven relapses occurred. Median follow-up was 44.4 months. Overall survival was 100% at 48 months, overall disease-free survival was 81.11% at 48 months from day 180. PDN and pulsed HD-DXM were well tolerated; HD-DXM allows effective initial responses but less long lasting than PDN. This trial was registered at www.clinicaltrials.gov as #NCT00657410.